Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Status:
Completed
Trial end date:
2016-03-14
Target enrollment:
Participant gender:
Summary
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients
with visual impairment due to macular edema secondary to CRVO